Therapeutic Asset Ratings
178 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Avelumab
Ureter Cancer
Emory University
P2
CCC
(48)
Avelumab
Urethra Cancer
Emory University
P2
CCC
(48)
Baricitinib
Major Depressive Disorder
Emory University
P2
CCC
(48)
Cyclophosphamide
Major Depressive Disorder
Emory University
P2
CCC
(48)
Dfn-15
Cancer
Emory University
P2
CCC
(48)
BMS-986345
Recurrent Diffuse Large B-Cell Lymphoma
Emory University
P1
CCC
(48)
Duvelisib
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Emory University
P1
CCC
(48)
TIPIRACIL
Cholangiocarcinoma
Emory University
P1/2
CCC
(48)
TIPIRACIL
Stage III Gastric Cancer
Emory University
P1/2
CCC
(48)
TIPIRACIL
Stage III Pancreatic Cancer
Emory University
P1/2
CCC
(48)
TIPIRACIL
Gastric Cancer
Emory University
P1/2
CCC
(48)
TIPIRACIL
Malignant Pancreatic Neoplasm
Emory University
P1/2
CCC
(48)
TIPIRACIL
Digestive System Carcinoma
Emory University
P1/2
CCC
(48)
TIPIRACIL
Exocrine Pancreatic Carcinoma
Emory University
P1/2
CCC
(48)
Trifluridine
Cholangiocarcinoma
Emory University
P1/2
CCC
(48)
Trifluridine
Stage III Gastric Cancer
Emory University
P1/2
CCC
(48)
Trifluridine
Stage III Pancreatic Cancer
Emory University
P1/2
CCC
(48)
Trifluridine
Gastric Cancer
Emory University
P1/2
CCC
(48)
Trifluridine
Malignant Pancreatic Neoplasm
Emory University
P1/2
CCC
(48)
Trifluridine
Digestive System Carcinoma
Emory University
P1/2
CCC
(48)
Trifluridine
Exocrine Pancreatic Carcinoma
Emory University
P1/2
CCC
(48)
Dfn-15
Neoplasm
Emory University
P2
CC
(46)
Vedolizumab
Major Depressive Disorder
Emory University
P2
CC
(46)
TEONANACATL
Hematopoietic And Lymphoid Cell Neoplasm
Emory University
P1
CC
(46)
Vidutolimod
Metastatic Prostate Adenocarcinoma
Emory University
P2
CC
(45)
Showing 126 to 150 of 178 assets
Previous
Page 6 of 8
Next